Vanguard Group Inc. Has $196.48 Million Position in Tarsus Pharmaceuticals, Inc. $TARS

Vanguard Group Inc. increased its holdings in shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 5.6% during the fourth quarter, Holdings Channel reports. The fund owned 2,399,560 shares of the company’s stock after acquiring an additional 127,470 shares during the quarter. Vanguard Group Inc. owned about 0.06% of Tarsus Pharmaceuticals worth $196,476,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also made changes to their positions in TARS. Deep Track Capital LP increased its holdings in shares of Tarsus Pharmaceuticals by 71.4% during the 3rd quarter. Deep Track Capital LP now owns 3,000,000 shares of the company’s stock worth $178,290,000 after acquiring an additional 1,250,000 shares during the last quarter. M&T Bank Corp increased its holdings in shares of Tarsus Pharmaceuticals by 11,730.0% during the 4th quarter. M&T Bank Corp now owns 437,119 shares of the company’s stock worth $35,791,000 after acquiring an additional 433,424 shares during the last quarter. MPM Bioimpact LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 2nd quarter worth approximately $13,834,000. TimesSquare Capital Management LLC acquired a new position in shares of Tarsus Pharmaceuticals during the 3rd quarter worth approximately $15,898,000. Finally, Qube Research & Technologies Ltd increased its holdings in shares of Tarsus Pharmaceuticals by 86.1% during the 2nd quarter. Qube Research & Technologies Ltd now owns 459,436 shares of the company’s stock worth $18,612,000 after acquiring an additional 212,592 shares during the last quarter. 90.01% of the stock is owned by institutional investors and hedge funds.

Trending Headlines about Tarsus Pharmaceuticals

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Tarsus reported Q1 EPS of -$0.16, beating expectations for a -$0.40 loss, and revenue of $162.05 million, above the $149.60 million consensus. Article Title
• Positive Sentiment: The company said Q1 XDEMVY net product sales topped $145 million, up more than 85% year over year, and reaffirmed 2026 guidance of $670 million to $700 million in XDEMVY sales. Article Title
• Neutral Sentiment: Management also highlighted broader business momentum, including stronger prescribing trends and the start of a Phase 2 Lyme disease prevention trial for TP-05. Article Title
• Neutral Sentiment: LifeSci Capital and HC Wainwright mostly kept bullish ratings on Tarsus, but several firms slightly lowered near-term EPS estimates after the report, which could temper enthusiasm. Article Title
• Negative Sentiment: Lifescis Capital cut Q1, Q2, Q3 and FY2026 EPS estimates, and HC Wainwright trimmed FY2027-FY2029 estimates slightly, reflecting continued losses in the near term despite long-term optimism. Article Title

Analysts Set New Price Targets

TARS has been the topic of a number of recent analyst reports. HC Wainwright reissued a “buy” rating and set a $88.00 target price on shares of Tarsus Pharmaceuticals in a report on Monday, May 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a report on Tuesday, April 21st. Oppenheimer started coverage on Tarsus Pharmaceuticals in a report on Friday, April 24th. They issued an “outperform” rating and a $98.00 price objective on the stock. Wall Street Zen lowered Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, April 18th. Finally, Lifesci Capital raised Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Monday, March 16th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $90.67.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $61.21 on Friday. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.74 and a quick ratio of 3.82. The stock’s fifty day moving average price is $68.72 and its two-hundred day moving average price is $71.87. Tarsus Pharmaceuticals, Inc. has a one year low of $38.51 and a one year high of $85.25. The firm has a market cap of $2.63 billion, a price-to-earnings ratio of -53.69 and a beta of 0.52.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Wednesday, May 6th. The company reported ($0.16) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.24. Tarsus Pharmaceuticals had a negative return on equity of 14.19% and a negative net margin of 9.02%.The firm had revenue of $162.05 million for the quarter, compared to analyst estimates of $149.60 million. On average, equities analysts forecast that Tarsus Pharmaceuticals, Inc. will post -0.7 EPS for the current year.

Insider Transactions at Tarsus Pharmaceuticals

In other news, insider Dianne C. Whitfield sold 4,174 shares of the company’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total transaction of $279,658.00. Following the completion of the sale, the insider directly owned 35,028 shares in the company, valued at approximately $2,346,876. This represents a 10.65% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bobak R. Azamian sold 11,964 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $801,588.00. Following the sale, the chief executive officer owned 33,421 shares of the company’s stock, valued at approximately $2,239,207. The trade was a 26.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 79,391 shares of company stock valued at $5,432,035. Corporate insiders own 8.97% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.